14 / 23
Page 60
allied
academies
J Med Oncl Ther 2017 | Volume 2 Issue 4
Oncology and Biomarkers Summit
November 27-28, 2017 | Atlanta, USA
Annual Congress on
P
rostate cancer is the most common cancer type in men
and is the second cause of death, due to cancer, in patients
over 50, after lung cancer. Prostate specific antigen (PSA) is
a widely-used tumor marker for prostate cancer. Recently,
PSA is discovered in non-prostatic cancer tissues in men
and women raising doubts about its specificity for prostatic
tissues. PSA exists in low serum level in healthy men and in
higher levels in many prostate disorders, including prostatitis
and prostate cancer. Thus, a supplementary tumor marker is
needed to accurately diagnose the cancer and to observe the
patient after treatment. Recently, soluble human leukocyte
antigen-G (sHLA-G) has been introduced as a new tumor
marker for different cancer types, including colorectal, breast,
lung and ovary. The present descriptive-experimental study
was carried out including patients with malignant prostate
tumor, patients with benign prostate tumor and a group of
health men as the control group, as judged by an oncologist
as well as a pathologist. After sterile blood sampling, sHLA-G
was measured by enzyme-linked immunosorbent assay
in each group. The data was then analyzed using one-way
ANOVA. P≤0.05 was considered as statistically significant.
The results showed that the mean of sHLA-G level was high
in patients. Also, it was found that there was a significant
difference in sHLA serum level between the three groups.
The data revealed that sHLA-G can be a novel supplementary
tumor marker in addition to PSA to diagnose prostate cancer.
e:
barvetic@gmail.comEvaluation of sHLA-G levels in serum of patients with prostate cancer identify as a potential of tumor
marker
Mohamadreza Mashhoudi Barez
Shahid Beheshti University, Tehran